A recent Financial Times report stated that Merck MRK is in talks to buy Redwood City, CA-based cancer biotech, Revolution Medicines RVMD, in a transaction that could value RVMD for up to $32 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results